Nurexus Logo

Association of Red Cell Distribution Width with Disease Activity in Systemic Lupus Erythematosus

P Keerthana, O Oviya

Paper ID : JMRP-10-2026-147

Published Date : October 31, 2026

DOI : 10.65188/nurexus.1106

Volume 4, Issue 10

Original Articles

Open AccessOpen Access
Peer ReviewedPeer Reviewed

Keerthana P, Oviya O. Association of Red Cell Distribution Width with Disease Activity in Systemic Lupus Erythematosus. Nurexus; Journal of MedVerse Research & Practice. 2026;4(10):1-8. doi: 10.65188/nurexus.1106. Available from: https://nurexus.com/journals/published/JMRP-10-2026-147

Download PDF

Abstract

Background: Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disorder characterised by diverse clinical manifestations and fluctuating levels of disease activity. Red cell distribution width (RDW), a routinely measured haematological index, has emerged as a potential indicator of systemic inflammation and may provide additional insight into disease activity in patients with SLE. Methods: This hospital-based observational study was conducted among 60 patients with SLE at Assam Medical College and Hospital, Dibrugarh. Disease activity was evaluated using the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). RDW, other haematological indices, inflammatory markers and complement levels were assessed. Statistical analysis was performed using Pearson's correlation coefficient and the independent-samples t-test. Results: The mean age of the study population was 29.45 ± 8.57 years, with females comprising 95% of the participants. Based on SLEDAI-2K scores, 37 patients (61.7%) had scores below 10, while 23 (38.3%) had scores of 10 or higher. Mean RDW was significantly elevated in patients with high disease activity compared with those with low disease activity (17.38 ± 2.74% versus 14.57 ± 1.96%; p < 0.001). RDW showed a significant positive correlation with SLEDAI-2K scores (r = 0.579, p < 0.001), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), whereas negative correlations were observed with complement C3 and C4 levels. Conclusion: RDW demonstrated a significant association with disease activity in patients with SLE, suggesting its potential role as an inexpensive and readily accessible adjunctive haematological marker. Further prospective studies involving larger populations are necessary to validate these findings and determine its clinical usefulness in routine disease monitoring.

Keywords:

Systemic lupus erythematosus
Red cell distribution width
Disease activity
SLEDAI-2K
Erythrocyte sedimentation rate
C-reactive protein
Complement levels
Keerthana P et al | DOI: 10.65188/nurexus.1106
Nurexus | Journal of MedVerse Research and Practice | ISSN: 3107-4278 | Volume 4 | Issue 10 | October 2026
Page 1
Journal of MedVerse Research & Practice
ISSN: 3107-4278
Association of Red Cell Distribution Width with Disease Activity in Systemic
Lupus Erythematosus
P Keerthana
1
, O Oviya
2
Postgraduate, Professor
Department of General Medicine, Dr. YSR University of Health Sciences, Vijayawada
Email ID: keerthanap787@gmail.Com
Submission Date: 02.09.2026
Accepted Date:11.10.2026
Published Date: 31.10.2026
DOI: 10.65188/nurexus.1106
Copyright © 2026. The author(s). Published by Journal of MedVerse Research and Practice. This is an open-
access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which
permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and
source are credited.
Abstract
Background: Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disorder characterised by
diverse clinical manifestations and fluctuating levels of disease activity. Red cell distribution width (RDW), a routinely
measured haematological index, has emerged as a potential indicator of systemic inflammation and may provide
additional insight into disease activity in patients with SLE.
Methods: This hospital-based observational study was conducted among 60 patients with SLE at Assam Medical
College and Hospital, Dibrugarh. Disease activity was evaluated using the Systemic Lupus Erythematosus Disease
Activity Index 2000 (SLEDAI-2K). RDW, other haematological indices, inflammatory markers and complement levels
were assessed. Statistical analysis was performed using Pearson's correlation coefficient and the independent-samples
t-test.
Results: The mean age of the study population was 29.45 ± 8.57 years, with females comprising 95% of the participants.
Based on SLEDAI-2K scores, 37 patients (61.7%) had scores below 10, while 23 (38.3%) had scores of 10 or higher.
Mean RDW was significantly elevated in patients with high disease activity compared with those with low disease
activity (17.38 ± 2.74% versus 14.57 ± 1.96%; p < 0.001). RDW showed a significant positive correlation with
SLEDAI-2K scores (r = 0.579, p < 0.001), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), whereas
negative correlations were observed with complement C3 and C4 levels.
Conclusion: RDW demonstrated a significant association with disease activity in patients with SLE, suggesting its
potential role as an inexpensive and readily accessible adjunctive haematological marker. Further prospective studies
involving larger populations are necessary to validate these findings and determine its clinical usefulness in routine
disease monitoring.
Keywords: Systemic lupus erythematosus; Red cell distribution width; Disease activity; SLEDAI-2K; Erythrocyte
sedimentation rate; C-reactive protein; Complement levels.
Introduction
Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disorder characterised by a
relapsing and remitting clinical course, heterogeneous manifestations, and variable disease outcomes. It is
associated with the production of diverse autoantibodies, of which antinuclear antibodies (ANA) exhibit
high sensitivity, while anti-double-stranded DNA and anti-Smith antibodies possess greater diagnostic
specificity. SLE predominantly affects women of reproductive age, although its prevalence varies
considerably across ethnic and geographical populations. An epidemiological study conducted in India
reported a prevalence of 3.2 cases per 100,000 population, emphasising the need for more extensive
ORIGINAL ARTICLE
Keerthana P et al | DOI: 10.65188/nurexus.1106
Nurexus | Journal of MedVerse Research and Practice | ISSN: 3107-4278 | Volume 4 | Issue 10 | October 2026
Page 2
epidemiological investigations in the Indian population [1,2].
The exact aetiopathogenesis of SLE remains unclear and is believed to involve a complex interplay of
genetic predisposition, environmental factors, hormonal influences, and immune system abnormalities. The
disease can involve several organ systems, including the renal, musculoskeletal, mucocutaneous,
cardiovascular, respiratory, neurological, and haematological systems. Frequently reported clinical features
include fatigue, photosensitivity, cutaneous eruptions, oral ulcers, inflammatory arthritis, and serositis.
Among the major organ complications, lupus nephritis is particularly significant because of its association
with increased morbidity and the potential progression to chronic renal impairment [1,3].
Haematological abnormalities constitute an important component of SLE and may affect erythrocytes,
leukocytes, and platelets. Anaemia, leukopenia, and thrombocytopenia are commonly encountered and may
occur either independently or simultaneously. Anaemia of chronic inflammation is frequently observed;
however, nutritional deficiencies, impaired renal function, autoimmune haemolysis, and adverse effects of
medications may also contribute to its development. These alterations reflect the underlying inflammatory,
immunological, and haematopoietic disturbances associated with SLE [3].
Red cell distribution width (RDW) is a routinely reported parameter in the complete blood count that
quantifies the degree of variation in circulating erythrocyte size, a phenomenon referred to as anisocytosis.
Although traditionally employed in the differential evaluation of anaemia, RDW has increasingly attracted
interest as a potential indicator of systemic inflammation and disease severity. Inflammatory mediators may
interfere with erythropoiesis, erythrocyte maturation, and red blood cell survival, thereby increasing
heterogeneity in cell size. Previous investigations have demonstrated associations between elevated RDW
and inflammatory biomarkers, particularly erythrocyte sedimentation rate (ESR) and C-reactive protein
(CRP) [4,5].
In patients with SLE, emerging evidence suggests a relationship between RDW, inflammatory activity, and
overall disease severity. Hu et al. reported a significant association between RDW and the Systemic Lupus
Erythematosus Disease Activity Index (SLEDAI), indicating its potential usefulness in evaluating disease
activity [6]. Nevertheless, RDW is a nonspecific parameter and may also be influenced by several other
conditions, including iron deficiency, vitamin B12 and folate deficiencies, haemoglobinopathies,
haemolytic disorders, and renal dysfunction. Therefore, these potential confounding factors should be
considered when interpreting RDW values in patients with SLE. The primary objective was to assess RDW
levels among patients with SLE and determine their correlation with disease activity measured using the
Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K).
Materials & Methods
Study Design and Setting
A hospital-based observational study was conducted in the Department of General Medicine, Dr. YSR
University of Health Sciences, Vijayawada, Andhra Pradesh, India. The study was carried out over a period
of one year, from 1 July 2021 to 30 June 2022. The primary objective was to evaluate red cell distribution
width (RDW) as a potential marker of disease activity in patients with systemic lupus erythematosus (SLE).
Study Population and Sample Size
The study population comprised patients diagnosed with SLE who attended the outpatient departments or
were admitted to the inpatient wards associated with the Department of General Medicine. A total of 60
patients were consecutively enrolled after fulfilling the predefined eligibility criteria. The sample size was
calculated considering a 95% confidence interval, 90% statistical power, a standard deviation of 3.82% for
RDW, and an allowable difference of 1% from the true population value.
Inclusion and Exclusion Criteria
Keerthana P et al | DOI: 10.65188/nurexus.1106
Nurexus | Journal of MedVerse Research and Practice | ISSN: 3107-4278 | Volume 4 | Issue 10 | October 2026
Page 3
Patients aged 13 years and above who fulfilled the 2019 European League Against Rheumatism/American
College of Rheumatology (EULAR/ACR) classification criteria for SLE were included in the study.
Patients younger than 13 years, those unwilling to provide informed consent, and individuals with
haemoglobinopathies, other autoimmune disorders such as rheumatoid arthritis and inflammatory bowel
disease, malignant diseases, chronic liver disease, or chronic kidney disease were excluded to minimise
potential confounding factors that could influence RDW values.
Data Collection and Clinical Assessment
Following informed consent, a detailed clinical history was obtained, and a comprehensive physical
examination was performed using a predesigned proforma. Demographic characteristics, presenting
complaints, clinical manifestations, relevant medical history, and laboratory findings were systematically
documented. Disease activity was assessed using the Systemic Lupus Erythematosus Disease Activity
Index 2000 (SLEDAI-2K), a validated scoring instrument incorporating clinical and laboratory parameters
across multiple organ systems. Based on their SLEDAI-2K scores, patients were classified into two
categories: low disease activity, with scores below 10, and high disease activity, with scores of 10 or above.
Laboratory Investigations and RDW Measurement
Routine laboratory investigations included complete blood count, haemoglobin concentration, mean
corpuscular volume, mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, total
and differential leukocyte counts, platelet count, and erythrocyte sedimentation rate (ESR). Additional
investigations, including renal function tests, urinalysis, 24-hour urinary protein estimation, C-reactive
protein (CRP), antinuclear antibody testing, anti-double-stranded DNA antibody assessment, and serum
complement C3 and C4 levels, were performed as clinically indicated.
RDW was measured using a six-part automated haematology analyser (Sysmex XN-550). Venous blood
samples were collected in ethylenediaminetetraacetic acid (EDTA)-containing tubes for haematological
analysis. RDW was expressed as the coefficient of variation (RDW-CV), calculated by dividing the standard
deviation of red blood cell volume by the mean corpuscular volume and multiplying the result by 100. The
association between RDW and SLE disease activity was subsequently evaluated in relation to other relevant
clinical and laboratory parameters.
Statistical Analysis
The collected data were entered into Microsoft Excel and analysed using the Statistical Package for the
Social Sciences (SPSS), version 20.0. Quantitative variables were expressed as mean and standard
deviation, whereas categorical variables were summarised as frequencies and percentages. Differences in
categorical variables were assessed using the chi-square test. Pearson's correlation coefficient was
employed to determine the strength and direction of the relationship between RDW and SLEDAI-2K scores.
A p-value of less than 0.05 was considered statistically significant.
Ethical Considerations
Approval was obtained from the Institutional Ethics Committee before the commencement of the study.
Written informed consent was obtained from all participants or their legally authorised representatives,
wherever applicable. Confidentiality and privacy of participant information were maintained throughout
the study, and the research was conducted in accordance with established ethical principles for biomedical
research involving human participants.
Result
Table 1. Sociodemographic characteristics of patients with SLE (n = 60)
Category
Number (%)
≤19
9 (15.0)
20–29
24 (40.0)
30–39
22 (36.7)
40–49
4 (6.7)
Keerthana P et al | DOI: 10.65188/nurexus.1106
Nurexus | Journal of MedVerse Research and Practice | ISSN: 3107-4278 | Volume 4 | Issue 10 | October 2026
Page 4
≥50
1 (1.7)
Male
3 (5.0)
Female
57 (95.0)
Married
39 (65.0)
Unmarried
21 (35.0)
Mean age: 29.45 ± 8.57 years.
Figure 1: Age Distribution
Among the 60 patients with systemic lupus erythematosus, the majority belonged to the 20–29 years age
group (40%), followed by those aged 30–39 years (36.7%). Females constituted 95% of the study
population, with a female-to-male ratio of 19:1. Regarding marital status, 39 (65%) patients were married,
while 21 (35%) were unmarried. (Table 1 & Figure 1)
Table 2: Biochemical, haematological and inflammatory parameters in SLE patients with
SLEDAI 2K Score
Parameter
SLEDAI 2K <10
SLEDAI 2K ≥10
P value
Mean
Std.Deviation
Mean
Std.Deviation
Hemoglobin(g/dl)
11.14
2.06
9.16
1.11
<0.001
MCV (fl)
82.36
6.53
85.64
7.17
0.074
RDW (%)
14.57
1.96
17.38
2.74
<0.001
Serum
Creatinine(mg/dl)
0.79
0.37
1.62
1.12
<0.001
Platelet count
(x10
3
cells/mm
3
)
1.89
0.83
1.48
0.59
0.043
24HourUrinary
Protein(g)
0.77
0.71
2.40
1.16
<0.001
ESR (mm AEFH)
47.70
35.36
69.95
43.38
0.034
CRP (mg/dl)
0.60
0.49
1.36
1.10
0.001
C3 (mg/dl)
42.14
22.25
31.78
21.46
0.081
C4 (mg/dl)
10.09
5.91
7.69
6.18
0.140
Patients with high disease activity (SLEDAI-2K ≥10) had significantly higher RDW, serum creatinine, 24-
hour urinary protein, ESR, and CRP levels, along with lower haemoglobin and platelet counts, compared
with patients with SLEDAI-2K scores below 10 (p < 0.05). RDW was notably higher in the high-activity
group (17.38 ± 2.74%) than in the low-activity group (14.57 ± 1.96%; p < 0.001). Differences in MCV,
complement C3, and C4 levels were not statistically significant (p > 0.05).
0.0%
10.0%
20.0%
30.0%
40.0%
<19 20-29 30-39 40-49 >50
Age Group
Keerthana P et al | DOI: 10.65188/nurexus.1106
Nurexus | Journal of MedVerse Research and Practice | ISSN: 3107-4278 | Volume 4 | Issue 10 | October 2026
Page 5
Table 3: SLEDAI 2K score in SLE patients
SLEDAI 2K Score
Number of patients
Percentage
Mean±s.d
<10
37
61.7
5.89±1.66
>10
23
38.3
16±4.63
Total
60
100.0
Min-Max
2- 29
Among the 60 patients, 37 (61.7%) had a SLEDAI-2K score below 10, with a mean score of 5.89 ± 1.66.
The remaining 23 (38.3%) had a score of 10 or above, with a mean of 16.00 ± 4.63. The overall SLEDAI-
2K scores ranged from 2 to 29, indicating varying levels of disease activity among the study participants.
Table 4. Correlation of SLEDAI-2K Score with RDW, Haemoglobin, Inflammatory Markers,
and Platelet Count in Patients with SLE
Variable
SLEDAI 2K Score
r value
p value
RDW (%)
0.579
<0.001
Hemoglobin (g/dl)
-0.442
<0.001
CRP (mg/dl)
0.668
<0.001
ESR (mm AEFH)
0.449
<0.001
Platelet count (x10
5
cells/mm
3
)
-0.313
0.015
The correlation analysis demonstrated a statistically significant positive correlation between SLEDAI-
2K score and RDW levels (r = 0.579, p < 0.001), indicating that RDW increased with increasing
disease activity. CRP (r = 0.668, p < 0.001) and ESR (r = 0.449, p < 0.001) also showed significant
positive correlations with disease activity. In contrast, haemoglobin (r = −0.442, p < 0.001) and platelet
count (r = −0.313, p = 0.015) showed significant negative correlations.
Table 5: Correlation between SLEDAI 2K score and RDW values in anemic SLE and non-
anemic SLE patients
Variable
SLEDAI 2K SCORE
Anemia patient (39)
Non-anemic patient (21)
RDW (%)
0.595
0.595
0.530
<0.001
<0.001
0.013
15.9±2.70
15.9±2.70
15.17±2.56
A significant positive correlation was observed between RDW and SLEDAI-2K scores in both anaemic
patients (r = 0.595, p < 0.001) and non-anaemic patients (r = 0.530, p = 0.013). The correlation was
numerically stronger among anaemic patients, suggesting that RDW was associated with disease activity
irrespective of anaemia status.
Table 6: Correlation between RDW with C3 and C4 levels in SLE patients
Variable
RDW (%)
r value
p value
Keerthana P et al | DOI: 10.65188/nurexus.1106
Nurexus | Journal of MedVerse Research and Practice | ISSN: 3107-4278 | Volume 4 | Issue 10 | October 2026
Page 6
C3 (mg/dl)
-0.25
0.04
C4 (mg/dl)
-0.38
0.003
A significant negative correlation was observed between RDW and complement C3 (r = −0.25,
p = 0.04) and C4 levels (r = −0.38, p = 0.003). The findings indicate that higher RDW levels
were associated with lower complement levels, with a stronger negative co rrelation observed
for C4.
Discussion
The present study investigated the potential role of red cell distribution width (RDW) as an indicator of
disease activity in patients with systemic lupus erythematosus (SLE). The major finding was a significant
positive correlation between RDW and the Systemic Lupus Erythematosus Disease Activity Index 2000
(SLEDAI-2K) score (r = 0.579, p < 0.001). Furthermore, patients with high disease activity (SLEDAI-2K
≥10) exhibited significantly higher mean RDW values than those with lower disease activity (17.38 ± 2.74%
versus 14.57 ± 1.96%, p < 0.001). These observations indicate that increased RDW is associated with
greater disease activity and may provide additional information alongside established clinical and
laboratory parameters during the assessment of SLE.
The demographic profile revealed that most participants belonged to the young adult age group, with a
mean age of 29.45 ± 8.57 years. Females accounted for 95% of the study population, resulting in a female-
to-male ratio of 19:1. This distribution reflects the well-established female predominance of SLE,
particularly among individuals of reproductive age. Previous literature has emphasised the heterogeneous
nature of SLE and the importance of integrating clinical and laboratory findings for comprehensive disease
assessment, given its variable manifestations and clinical course [15].
The positive association between RDW and disease activity observed in the present study is consistent with
findings from earlier investigations. Previous research has demonstrated a significant correlation between
RDW and SLEDAI-2K scores, along with associations with erythrocyte sedimentation rate (ESR) and C-
reactive protein (CRP) [7]. Similarly, a positive relationship between RDW and disease activity has been
reported in both anaemic and non-anaemic patients with SLE, suggesting that this association is not
exclusively attributable to reduced haemoglobin levels [8].
More recent studies have provided further evidence supporting the relationship between RDW and SLE
activity. Significantly elevated RDW levels have been observed in patients with active SLE compared with
those with inactive disease, with a positive correlation between RDW and SLEDAI scores [9]. Associations
between RDW and various indicators of clinical and serological disease activity, including SLEDAI-2K
scores and inflammatory cytokines, have also been reported [10]. In a study involving 284 patients with
SLE and 181 healthy controls, RDW remained associated with disease activity and accumulated organ
damage even after adjustment for potential confounding variables [13]. Additional evidence from 2025 has
further highlighted the potential relevance of RDW in monitoring SLE activity. Higher RDW values have
been reported during lupus flares compared with periods of remission, along with a positive correlation
between RDW and SLEDAI-2K scores. However, the diagnostic performance of RDW differed depending
on the comparison group, suggesting that it may be more appropriately considered an adjunctive parameter
rather than an independent diagnostic marker [14].
An important observation in the present study was the persistence of a positive correlation between RDW
and SLEDAI-2K scores across both anaemic and non-anaemic subgroups. Among patients with anaemia,
the correlation coefficient was r = 0.595 (p < 0.001), whereas among non-anaemic patients, it was r = 0.530
Keerthana P et al | DOI: 10.65188/nurexus.1106
Nurexus | Journal of MedVerse Research and Practice | ISSN: 3107-4278 | Volume 4 | Issue 10 | October 2026
Page 7
(p = 0.013). Although the correlation was numerically stronger in the anaemic subgroup, this difference
cannot be considered statistically significant without a formal comparison between the correlation
coefficients. These findings suggest that the association between RDW and disease activity may extend
beyond the influence of anaemia alone. Similar observations have been reported, demonstrating a positive
association between RDW and SLEDAI-2K irrespective of anaemia status [8]. Additional evidence has
identified relationships between RDW, disease activity, and serological abnormalities, further supporting
its potential relevance in SLE assessment [10].
The present study also demonstrated significant relationships between conventional inflammatory markers
and disease activity. CRP exhibited the strongest positive correlation with SLEDAI-2K scores (r = 0.668,
p < 0.001), followed by ESR (r = 0.449, p < 0.001). In addition, RDW showed significant positive
correlations with ESR (r = 0.524, p < 0.001) and CRP (r = 0.496, p < 0.001). These findings suggest that
increased RDW may occur alongside heightened systemic inflammatory activity in patients with SLE.
Comparable associations between RDW, disease activity, and inflammatory parameters have been
documented in previous studies [9,10]. The association may reflect the influence of inflammatory processes
on erythropoiesis, red blood cell maturation, and erythrocyte survival. Nevertheless, the observed
correlations do not establish a direct causal relationship between inflammation and increased RDW.
An inverse association was identified between RDW and serum complement levels. RDW demonstrated a
significant negative correlation with complement C3 (r = −0.250, p = 0.040) and C4 (r = −0.380, p = 0.003).
These findings suggest that higher RDW values may be associated with lower complement levels in patients
with SLE. Previous research has similarly reported associations between haematological parameters and
hypocomplementemia in SLE [10]. Complement consumption is an important feature of immune complex-
mediated disease activity and may accompany active lupus manifestations. However, despite the significant
correlations, differences in mean C3 and C4 levels between the low- and high-disease-activity groups in
the present study were not statistically significant. This distinction highlights the need to interpret
correlation findings and between-group comparisons separately and cautiously. Several haematological
parameters were also associated with disease activity. Haemoglobin concentration demonstrated a
significant negative correlation with SLEDAI-2K scores (r = −0.442, p < 0.001), with lower mean
haemoglobin levels observed among patients with high disease activity. Similarly, platelet count showed a
significant inverse correlation with SLEDAI-2K scores (r = −0.313, p = 0.015).
Strengths and Limitations: An important strength of the present study was the systematic assessment of
RDW in relation to disease activity using the validated SLEDAI-2K scoring system. The evaluation of its
relationship with inflammatory markers, complement levels, and anaemia status provided a broader
understanding of the potential association between RDW and disease activity in SLE. However, certain
limitations should be acknowledged. The relatively small sample size and single-centre design may restrict
the generalisability of the findings to the wider SLE population. The observational nature of the study does
not permit the establishment of a causal relationship between RDW and disease activity.
Conclusion
The study demonstrated a significant positive association between RDW and SLE disease activity, with
higher RDW values observed among patients with elevated SLEDAI-2K scores. RDW also showed
significant relationships with inflammatory markers and serum complement levels, suggesting its potential
relevance in reflecting disease activity. These findings support the use of RDW as a simple, cost-effective
and readily accessible adjunctive parameter for disease activity assessment in patients with SLE. However,
further large-scale prospective studies are necessary to validate these observations and establish its clinical
applicability in routine practice.
Keerthana P et al | DOI: 10.65188/nurexus.1106
Nurexus | Journal of MedVerse Research and Practice | ISSN: 3107-4278 | Volume 4 | Issue 10 | October 2026
Page 8
Declaration
Conflict of Interest: The authors declare that they have no competing interests or conflicts of interest
related to this work.
Funding: Nil
Reference
1. Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, et al. Systemic lupus
erythematosus. Nat Rev Dis Primers. 2016;2:16039.
2. Malaviya AN, Singh RR, Singh YN, Kapoor SK, Kumar A. Prevalence of systemic lupus erythematosus in
India. Lupus. 1993;2(3):135-7.
3. Velo-García A, Castro SG, Isenberg DA. The diagnosis and management of the haematologic manifestations
of lupus. J Autoimmun. 2016;74:139-60.
4. Evans TC, Jehle D. The red blood cell distribution width. J Emerg Med. 1991;9 Suppl 1:71-4.
5. Salvagno GL, Sanchis-Gomar F, Picanza A, Lippi G. Red blood cell distribution width: A simple parameter
with multiple clinical applications. Crit Rev Clin Lab Sci. 2015;52(2):86-105.
6. Sun Y, Huang YL, Wang QQ, et al. Red blood cell distribution width is a potential index to assess the disease
activity of systemic lupus erythematosus. Clin Chim Acta. 2023;427:201-210.
7. Hu ZD, Chen Y, Zhang L et al. Red blood cell distribution width is a potential index to assess the disease
activity of systemic lupus erythematosus. Clin Chim Acta. 2013;425:202-205. doi:10.1016/j.cca.2013.08.007.
8. Zou XL, Lin XJ, Ni X, Wang J, Liu W, Wei J. Baseline red blood cell distribution width correlates with
disease activity and therapeutic outcomes in patients with systemic lupus erythematosus, irrespective of anemia
status. Clin Lab. 2016;62(10):1841-1850. doi:10.7754/Clin.Lab.2016.160213.
9. Zheng CS, Qin XJ, Ni H, Chen RY, Liu JL, Wang WH. Evaluation of disease activity of systemic lupus
erythematosus by D-dimer combined with red blood cell distribution width. Clin Lab. 2021;67(9).
doi:10.7754/Clin.Lab.2021.210118.
10. Moreno-Torres V, Castejón R, Mellor-Pita S, Tutor-Ureta P, Durán-Del Campo P, Martínez-Urbistondo M,
et al. Usefulness of the hemogram as a measure of clinical and serological activity in systemic lupus
erythematosus. J Transl Autoimmun. 2022;5:100157. doi:10.1016/j.jtauto.2022.100157.
11. Santacruz JC, Mantilla MJ, Rueda I, Pulido S, Rodriguez-Salas G, Londono J. A practical perspective of
the hematologic manifestations of systemic lupus erythematosus. Cureus. 2022;14(3):e22938.
doi:10.7759/cureus.22938.
12. Pamuk ON. Thrombocytopenia in patients with systemic lupus erythematosus. Eur J Rheumatol.
2023;10(4):159-162. doi:10.5152/eurjrheum.2023.23069.
13. Mercader-Salvans J, García-González M, Quevedo-Abeledo JC, Quevedo-Rodríguez A, Gómez-Bernal F,
Hernández-Díaz M, et al. Red blood cell distribution width as a surrogate biomarker of damage and disease
activity in patients with systemic lupus erythematosus. Clin Exp Rheumatol. 2024;42(9):1773-1780.
doi:10.55563/clinexprheumatol/f0jnnm.
14. Ajmi M, Riahi S, Ben Hassine I, Ben Cheikh A, Dhaha Y, Mbarki D, et al. Complete blood count-derived
biomarkers as indicators of systemic lupus erythematosus activity: a cross-sectional comparative study. Lupus
Sci Med. 2025;12(2):e001795. doi:10.1136/lupus-2025-001795.
15. Lazar S, Kahlenberg JM. Systemic lupus erythematosus: new diagnostic and therapeutic approaches. Annu
Rev Med. 2023;74:339-352. doi:10.1146/annurev-med-043021-032611.
16. Fayyaz A, Igoe A, Kurien BT, Danda D, James JA, Stafford HA, et al. Haematological manifestations of
lupus. Lupus Sci Med. 2015;2(1):e000078. doi:10.1136/lupus-2014-000078.